Stock Market & Financial Investment News

Jazz Pharmaceuticals and Gentium announce Europcean launch of DefitelioJazz Pharmaceuticals and Gentium S.p.A., a Jazz Pharmaceuticals company, announced the commencement of the European commercial launch of Defitelio, the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.1 The companies have launched Defitelio in Germany and Austria and expect to continue the launch in 27 additional European countries on a rolling basis during 2014 and 2015.

Jazz Pharmaceuticals pullback a buying opportunity, says JPMorganJPMorgan says Jazz Pharmaceuticals' weaker than expected 2015 earnings outlook was not driven by any softness in the company's core driver, Xyrem, but rather non-operating/one-off issues. The firm recommends using the share sell-off as a buying opportunity and keeps an Overweight rating on Jazz with a $190 price target.